CCHT has formed the development platform for three industries including ge
Changchun High-tech Industry, founded in 1993 and was listed at Shenzhen Stock Exchange in 1996. It has established its industrial orientation with the biopharmaceutical industry as the primary and real estate industry as the supplement, has formed the development platform for three industries including genetic engineering pharmaceuticals, biological vaccines and modern traditional Chinese medicine. The main shareholders are Changchun Gaoxin Chaoda Investment Company, Jin Lei and Lin Dianhai. The company's direct and indirect competitors include Yongan Pharmaceutical, Da An Gene and Beijing Genomics Institute.
Big Pharma CCHT’s Domination Unlikely to Fade Soon Despite Official Bulk Buying
The producer of long-acting growth hormone acupunctures, vaccines and other drugs, looks set to offset the effects of so-called “centralized procurement” on its product prices with more aggressive expansion into private hospitals. So far, its monopoly appears unshakable, but with more competitors upping the stakes, how long will it last?
Feb 21, 2022 02:30 PM
ResearchHealthcare, Technology, Consumer Staples
WIA2020 | Rising Tech Stars 2020: Global & China's 100
China's Road to Tackle Autoimmune Diseases Globally
The market of autoimmune diseases medication is vast both in China and overseas and presents great opportunities. However, the number of Chinese players specializing in autoimmune diseases is limited. This article introduced the autoimmune diseases medication market in China and explained why Chinese players are limited then give some recommendations on what efforts Chinese companies can make to compete with western players.
Oct 04, 2022 08:00 AM
15 Companies to Watch in September 2022- Healthcare
Editor's note: We at EqualOcean tracked the major funding rounds or industry events that took place in China's healthcare space in September 2022. And the following is a list of deals that we have selected for you, based on a number of criteria, including the funding amount, the financial backers, and the segments in which the startups operate.
Sep 30, 2022 12:32 PM
Ubrigene Bags Hundreds of Mns of CNY in Series C Financing Round
Ubrigene, dedicated to providing one-stop CDMO services for cell and gene therapies, will continue to improve its management system and incubate more specialized technology platforms with the fresh proceeds.
Sep 27, 2022 06:35 PM